Molecular diagnostics is one of the transformative and dynamic areas of diagnostic, leading to advances in treatment and research that are modernizing and developing healthcare across broad range of infectious diseases and health conditions. Currently, the market for infectious disease molecular diagnostics tests is considerably promising and profitable due to the increasing adoption rate of molecular diagnostic technologies along with escalating incidence rates of infectious diseases the market is expected to grow substantially.
Download exclusive Sample of this report
Some of the molecular diagnostic technologies used in infectious disease testing are as follows:
- Mass spectrometry (MS)
- Capillary electrophoresis
- Next generation sequencing (NGS)
- Chips and microarray
- In situ hybridization (ISH or FISH)
The major infectious diseases for which molecular diagnostic tests can be performed are as follows:
- HPV/ cervical cancer
- Diarrheal Diseases
Based on end-users the market for infectious disease molecular diagnostics tests can be segmented as follows:
- Blood banks
- Reference laboratories
In terms of regional distribution, North America followed by Europe account for the largest market share of infectious disease molecular diagnostics tests market due to the market availability of the tests and high incidence rate of various infectious disease such as HPV, hepatitis and bacterial infections. According to an article published in the World Journal of Hepatology, each year around 1.5 million clinical cases of hepatitis A occur globally. In addition, other regions such as Asia Pacific, Latin America as well as Middle East, are expected to be the potential markets in the near future. Due to the high adoption rate of advanced molecular diagnostic tests and exponentially growing healthcare industry, these regions are expected to be the potential market in the near future.
View exclusive Global strategic Business report
Across the globe, the overall infectious disease molecular diagnostics tests market is witnessing a considerable pressure and rapid development. Moreover, increasing incidence rate of infectious diseases such as respiratory diseases, bacterial infections, HIV and HPV are expected to boost the market growth of the infectious disease molecular diagnostic tests market in the near future. For instance, according to the UNAIDS (The Joint United Nations Programme on HIV/AIDS), in 2012, approximately 1.3 million people were living with HIV, in the U.S. Furthermore, the WHO claims that, at the end of 2013, globally, approximately, 35 million individuals were living with HIV. Thus, this large base of HIV patients is expected to drive the market growth of infectious disease molecular diagnostic tests market across the globe. Furthermore, advantages of molecular diagnostic tests such as ability to identify multiple strains of respiratory viruses and ability to monitor the level of HIV virus in the person’s blood for determining the type of treatment would contribute to the growth of this market. However, high cost of these tests and availability of the tests kits are some of the factors that might negatively influence the growth of this market.
Currently, the global infectious disease molecular diagnostics tests market is highly fragmented and competitive owing to the presence of many global as well as emerging players in the infectious molecular diagnostic tests market. The market is expected to witness a significantly high growth rate due to the increasing incidence of infectious diseases and introduction of advanced diagnostic technologies in the field healthcare industry. Major companies operating in the field of infectious disease molecular diagnostics tests market are Abbott Laboratories, Affymetrix, Inc., Becton, Dickinson and Company, bioMérieux, Cepheid, Inc., Hologic, Inc., Life Technologies, Myriad Genetics, Inc., Qiagen N.V. and others.